Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC from HOLD to BUY.
BY Investars Analyst Actions - private
— 2:10 AM ET 02/01/2019
Zacks Investment Research, Inc. downgrades ORGANOVO HOLDINGS INC from BUY to HOLD.
BY Investars Analyst Actions - private
— 2:10 AM ET 01/31/2019
Do these guys have any clue at all? It doesn't look like it. No change and they bounce between buy and hold daily. Useless information IMO...
Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC from HOLD to BUY.
BY Investars Analyst Actions - private
— 2:10 AM ET 01/30/2019
Right now, I think ONVO is following the market down
Well, no comment on your trades, but when I see these spec stocks like this drop from unrelated market movements I wonder if it's a buy sign.
Nothing has ever worried me about this company with their technology. It's just a matter of time 3D Bioprinting is intrinsically very valuable imo
I'm mixed on the buyout possibilities, since on one hand, a buyout limits the upside to the deal they get. Although a deal could include stocks in the company that buys out ONVO, and that way shareholders stay along for the ride.
But if Organovo follows through right through trials the upside there is staggering to think about. I'm convinced of the eventual realization of transplantable, DNA matched, 3D bioprinted replacement animal and human organs
just sayin...
Analyst Actions: HC Wainwright Starts Organovo at Buy, With $2.50 Price Target
BY MT Newswires
— 9:06 AM ET 12/13/2018
Accounting & Governance Risk Overview: Organovo Holdings Inc
BY Audit Integrity Research
— 2:00 AM ET 11/26/2018
Organovo Holdings Inc ( ONVO ) is currently rated as having Average Accounting & Governance Risk (AGR®), receiving an AGR score that places them in the 72nd percentile among all companies in North America rated by GMI, indicating higher accounting and governance risk than 28% of the other companies.
Accounting & Governance Risk Overview: Strikeforce Technologies Inc
BY Audit Integrity Research
— 2:00 AM ET 11/26/2018
Strikeforce Technologies Inc ( SFOR ) is currently rated as having Conservative Accounting & Governance Risk (AGR®), receiving an AGR score that places them in the 88th percentile among all companies in North America rated by GMI, indicating higher accounting and governance risk than 12% of the other companies.
None of that Israeli research is anywhere near being approved for humans. They are about where Organovo was 5 years ago, so ONVO has at least 5 years on them. They might be able to "grow" some small tissue samples as they said, some day, but they are a LONG way from anything real. Nice find though.
Just noticed an article about someone needing bone marrow transplant due to leukemia. Not sure if bone marrow can be grown with stem cells, but they wouldn't need to print bone marrow in zero G, so that's another thing to consider. There's just so much that could be done with ONVO's technology. It'll be one of those things that happens fast I think. The initial acceptance isn't far off, and once that happens, there could be a snow ball effect.
Good travels and happy holidays
What would you think of a tie up with SpaceX and Organovo? NASA is sending a 3D printer up so fewer spares will be needed to be ferried up and down. Got me thinking. Spacex, with Organovo could put a bioprinter on a satellite to print organs. They can later retrieve the finished organ(s), and return them on a landing booster.
If Elon Musk's SpaceX could put Organovo's 3D bioprinters on satellites for making replacement organs, ONVO has good IP which could make things very interesting. Very good IP. And, it makes sense to 3D Bioprint full organs in zero G. Once you get the system in orbit, all you need is the bioink of which they already have a supply line in place... so, hell, I could engineer that system. So someone else could too. And that's just one thing I can think of, just sayin that makes ONVO still interesting.
Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC from HOLD to BUY.
BY Investars Analyst Actions - private
— 2:10 AM ET 11/15/2018
On November 15, 2018 Zacks Investment Research, Inc. upgraded ORGANOVO HOLDINGS INC ( ONVO from HOLD to BUY.
3 dimensional printed human tissue. Man I feel like we're living in a science fiction.
Scientists Just Engineered Human Heart Tissue That Beats Like The Real Thing
https://www.sciencealert.com/scientists-grow-heart-tissue-that-beats-like-the-real-thing
"If you have doubts about the progress scientists are making in growing tissue in the lab, check out this incredible artificial heart tissue that beats just like the real thing - it's both haunting and fascinating to watch."
Organovo should have enough business going in the samples/ toxicology market to sustain the company for the time needed to get through clinical trials. It's a good company with really good management and staff, so far as I've seen. And even more likely than them going broke would be a tie-up with a big deep pocket entity for funding the trials. Just kidney tissue alone for diabetic patients that are receiving dialysis treatment is a huge market. Then there is liver tissue for Hepatitis type patients, (and heavy drinkers!) Skin grafts for burns victims is another huge market. Don't forget the 700lb gorilla for this technology is the military. In my opinion, the silence on that subject is deafening. The list goes on and on. Just so much upside potential IMHO.
Although I agree with your assessment of a business model of ongoing therapy having more profit than a cure, I don't share your cynicism regarding the way things work in the medical field regarding disruptive therapies. EVERY large biotech firm out there would have to sit by and watch this monster potential die on the vine hoping to be the lucky one to buy it up dirt cheap.
Replacing diseased or damaged organ tissue isn't necessarily a cure, but could in many cases be a stop gap therapy that needs to be re-applied. And once Medicaid or Medicare and/or private insurance companies get on board, ONVO could sky rocket.
Just sayin...
What do you think the divesting of their old business will net positive or negative cash? Also, what effect will the name change have?
Organovo to Present New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Tyrosinemia I at the Liver Meeting® 2018 (AASLD)
BY GlobeNewswire
— 8:05 AM ET 10/15/2018
The Company’s poster(s) and oral presentation are as follows:
Title: The Performance Characteristics of Isolated Human Liver Cells Correlate
with Donor Attributes in a Cohort of Tissues from Non-Diseased and NAFLD Donors
Date: Saturday, November 10, 2018, 2:00 pm PT – Moscone Center
North/South
Building, Hall C
Publication: 1305
Title: Long-Term Performance of Implanted Bioprinted Human Liver Tissue in a
Mouse Model of Tyrosinemia I (Oral Presentation)
Date: Sunday, November 11, 2018, 11:30 am PT – Moscone Center North/South Building, Room 214/216
Publication: 0083
About Organovo Holdings, Inc. ( ONVO) is a biotech platform company that has developed a leadership position with its revolutionary ability to 3D bioprint tissues with human functionality. The Company is pursuing multiple IND-track programs to develop its NovoTissues® to address a number of serious unmet medical needs in adult and pediatric populations, initially focusing on liver disease. Organovo’s first IND-track program for Alpha-1-antitrypsin deficiency recently received orphan drug designation from the FDA, and the Company expects to file its first IND in 2020. In order to support its plan to initiate multiple IND-track programs, the Company is providing access to its ExVive™ in vitro tissue disease modeling platform to facilitate high value drug discovery and development collaborations. Organovo’s wholly-owned subsidiary, Samsara Sciences, provides the Company and its clients with high quality human liver and kidney cells for research applications. Organovo ( ONVO) is changing the shape of life science research and transforming medical care. Learn more at www.organovo.com.
My my my how can I resist. Every heard of instant gratification? Growing transplantable replacement tissue for humans take time. This is not only a good tradable ticket IMO, it's an investment in what could be the biggest disruption. Ever.
Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC from SELL to HOLD.
BY Investars Analyst Actions - private
— 7:05 AM ET 09/05/2018
On September 5, 2018 Zacks Investment Research, Inc. upgraded ORGANOVO HOLDINGS INC ( ONVO ) from SELL to HOLD.
Pandora Media's Strong Financials Means Upgrade at Barrington as Company Successfully Monetizes Ads
BY MT Newswires
— 12:56 PM ET 08/06/2018
MT NEWSWIRES – 12:56 PM ET 08/06/2018
Barrington upgraded its rating to outperform and put an $11 price target on the company.
Can't resist under a $1 for this. Let's see if those predictions for $2.50 hold up to reality in the next quarter or so :)
Cheers!
Looking forward to replacement organs? Keep watching ONVO.
Another short seller trying really hard to bring ONVO down.
There's a three page dissertation on the hopes and dreams of a short seller of ONVO, but at least it ends with an honest Disclosure: I am/we are short ONVO.
https://seekingalpha.com/article/4191997-organovo-needs-business-transplant
The comments section were a bit more interesting.
Disclosure, still accumulating and trading this. Grabbed a bunch of shares at 1.15, flipped them for 1.25. Not a bad day here :)
Notice anything interesting at the end of the day the last couple Fridays?
And so begins the slow crawl back to 2. I wonder how long it'll take this time. Probably faster than last time. Fewer and fewer people letting their shares go. I wish some of my other investments were this easy.
Pfizer to invest $600 mln in venture capital arm
BY MarketWatch
— 8:14 AM ET 06/06/2018
Could be the precursor to this eventual buy out?
Best case scenario for us would be a bidding war between Pfizer and Merck or Sanofi or even Boston Scientific :)
Having said all that, ONVO under $2 IMO is still super cheap
Even if they have to go it alone on the liver patch, or kidney replacement therapy, the eventual value of transplant therapy is in the tens of billions. And from the looks of it, Organovo has the lion''s share of related IP, some good history of getting the patented technology working for testing , and the advantage of getting their technology in front of the FDA first.
That's awesome. Might be good to get back in at 1.35. Rinse and repeat. Love this ticker!
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Organovo Holdings ( ONVO ), Inc. (“Organovo”) today announced that it will present new preclinical data showing the strong functionality of its liver therapeutic tissue in a second IND-track program for Type 1 Tyrosinemia. This data will be presented at the World Advanced Therapies and Regenerative Medicine Congress in London on May 18, 2018 by Benjamin Shepherd, Ph.D., Senior Director of Therapeutics, at Organovo ( ONVO ).
Type 1 Tyrosinemia is a rare disease characterized by a patient’s inability to metabolize the amino acid tyrosine due to a deficiency of the enzyme fumarylacetoacetate hydrolase. This disorder frequently causes severe liver damage, with current treatment options often limited to organ transplantation. Organovo ( ONVO ) recently studied the potential benefit of its NovoTissues® in an established animal model for Type 1 Tyrosinemia, and showed retention and sustained functionality post-implamantation. Pathologic evaluation of the diseased animals receiving implanted bioprinted liver tissues also suggested an improvement in liver health and extended survival versus non-treated animals.
The Company will also summarize its ongoing progress in its first IND-track program for its NovoTissues treatment of alpha-1 antitrypsin deficiency (“A1AT”). This indication, which received orphan drug designation from the U.S. Food & Drug Administration in 2017, similarly represents a patient population that is in desperate need of new treatment options. Organovo ( ONVO ) previously disclosed the results of its preclinical studies in an established animal model for A1AT. Serum and histopathologic evaluation of the implanted therapeutic tissue showed engraftment, retention and a high degree of disease clearing through 125 days post-implantation. These results also demonstrated the sustained presence of key human liver proteins such as albumin and A1AT in the animal bloodstream. Importantly, pathologic evaluation of diseased animals receiving implanted bioprinted liver tissues suggested a significant reduction in the pathologic hallmarks of the disease in the damaged region of the liver adjacent to the NovoTissues transplant.
“We’re encouraged that our 3D bioprinted liver tissues continue to show retention and functionality in a range of animal disease models, including two disease areas where there is critical unmet need and a significant impact on patient outcomes because of the dire shortage of liver transplants,” said Dr. Benjamin Shepherd, senior director of therapeutics, Organovo. “In each case, our objective in implanting a healthy tissue patch is to restore function or offset the deficiency of a specific enzyme abnormality, with the ultimate goal of delaying or reducing the need for a transplant.”
“We are delighted with the early readouts of these complementary therapeutics programs,” said Taylor J. Crouch, CEO, Organovo. “The results in this second disease area within the orphan group of inborn errors of metabolism support the opportunity for a synergistic, second IND-track that we will likely pursue alongside our lead IND-track program for A1AT deficiency. There is great utility in deploying a single implanted tissue to treat multiple diseases, all of which are life-threatening and have few alternative treatment options.”
Hope your still holding here. Just a matter of time this breaks $2 again. Still expecting buy out news any day.
Organovo to Present New Preclinical Data for Its Liver Therapeutic Tissue IND-Track Programs at the World Advanced Therapies and Regenerative Medicine Congress
BY GlobeNewswire
— 8:05 AM ET 05/10/2018
Organovo’s 3D bioprinted human liver tissues function for at least four weeks and are comprised of a complex multicellular architecture that more closely emulates human biology and disease. The Company’s tissue systems have the potential to facilitate breakthrough translational research from target discovery to high-value drug profiling, enabling better understanding of disease processes, discovery of novel therapeutics, biomarkers, and the safety assessment of drugs in a disease-relevant background.
Organovo to Present at 2nd Annual NASH Summit
BY GlobeNewswire
— 8:05 AM ET 04/24/2018
Event: 2nd Annual NASH Summit
Presentation Title: Modeling NAFLD/NASH In Vitro Using 3D Bioprinted Human Liver Tissue
Date & Time: Thursday, April 24th at 4:00pm ET
Location: Revere Hotel Boston Common, Boston, Ma.
Organovo Jumps 5% Premarket After Reporting Several Breakthroughs With 3D Bioprinted Tissues
BY MT Newswires
— 9:30 AM ET 04/16/2018
Won't be much longer part of the transplant waiting list diminishes once Organovo's livers become approved.
Nearly 115,000 people are on the waiting list for an organ transplant in the United States alone, and last year there were just 34,770 transplants performed. Thousands die waiting. Partly, there are too few donations. Also, donated organs can't be stored for long — about four to six hours for a heart or lung, and about 12 hours for a liver. And sometimes surgeons discard organs they fear won't do well because of a donor's age or other health characteristics.
http://abcnews.go.com/Health/wireStory/warming-cooling-donated-livers-improve-transplants-54562192
What's the best case scenario where VHC cashes a check from AAPL, and the millions hit their books? Weeks? Months? Years? call it 600 million, at 60~million shares out, that's a simple $10 a share gain. X2 for the market, good will... $20? $25? well...
No matter what the details, it ends up the same, at this market cap VHC has bubble written all over it. And it hasn't even started yet. Additional millions on top of the $502 million for expenses etc....
I imagine this much cash erases VHC debt completely. More than likely commons will even see a dividend. Those are always sweet.
I might take a piece of this. Even if ya have to wait a bit for the payoff. Should hold up in fours 'till the next shoe drops, then no reason this doesn't hit $20. Unless a buyout springs up, then it could hit $30 or more if a bidding war starts up.
SAN DIEGO and KALAMAZOO, Mich., April 12, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it presented a late-breaking poster describing the activity of the company's lead drug MSDC-0602K in a three-dimensional bioprinted human tissue model of NASH at The International Liver Congress(TM) -- occurring in Paris, France from April 11-15, 2018.
The poster, entitled "A human in vitro three-dimensional bioprinted tissue system can be used to model nutritional damage and protective effects of MSDC-0602K, a novel modulator of the mitochondrial pyruvate carrier" presented work performed using Organovo's ( ONVO ) 3D bioprinted human liver tissue and was presented by Dr. Jerry Colca from Cirius Therapeutics.
The research demonstrated that adding fructose (sugar) and fatty acids to three-dimensional bioprinted human liver tissue produced NASH-type liver pathology, including steatosis, inflammation, ballooning and fibrosis. Addition of MSDC- 0602K to the tissue showed evidence of reduced disease progression, including reductions in collagen deposition and stellate cell activation, in the liver model.
"The data shown in this human liver model demonstrates conclusively that oversupply of nutrients leads directly to NASH-like pathology, including fibrosis," said Dr. Colca. "In addition, we see in this 3-D tissue model evidence that treatment with MSDC-0602K, which modulates metabolism by slowing the transport of the important metabolic intermediate pyruvate into the mitochondria, reduces signs of NASH. This supports our thesis that restoring nutritional balance on a cellular level has potential to treat NASH."
This work follows recently published work demonstrating that attenuation of pyruvate metabolism with MSDC-0602K via modulation of the mitochondrial pyruvate carrier (MPC) can both prevent and reverse liver fibrosis.
"The ability to model human liver disease and drug intervention with our technology is a powerful tool for helping companies such as Cirius evaluate their drug candidates for the treatment of NASH," Paul Gallant, general manager, Organovo ( ONVO ). "As the results of this research show, it can also yield valuable insights about potential biomarkers that can be monitored during liver disease progression."
Organovo Holdings Presents Data on Modeling Liver Disease Using 3D Bioprinted Human Liver Tissue
BY MT Newswires
— 9:30 AM ET 04/12/2018
09:30 AM EDT, 04/12/2018 (MT Newswires) -- Organovo Holdings ( ONVO) was out Thursday with data on modeling non-alcoholic fatty liver disease (NAFLD) using its 3D bioprinted human liver tissues.
The company said its NAFLD disease model can now demonstrate a progressive accumulation of fat over time, creating a window of disease progression onto which candidate drugs targeted at fat accumulation and disposition can be applied.
In addition, the company said it has established that the NAFLD disease phenotype can be generated from multiple donor origin cells, and that the inherent variability between donors is reflected in the NAFLD model as variable susceptibility to tissue damage by NAFLD-promoting agents. These new data provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants, the company added.
VirnetX Awarded $502.6 Million Jury Verdict Against Apple
Jury Finds Apple Willfully Infringed
ZEPHYR COVE, Nevada.,– 4/12/2018 – VirnetX™ Holding Corporation (NYSE AMERICAN: VHC), an Internet security software and technology company, announced today that a jury in the United States Court for the Eastern District of Texas, Tyler Division, in the case VirnetX Inc., et al. v. Apple Inc., No. 6:12-CV-00855-LED) (“Apple II”) has awarded VirnetX $502.6 million in a verdict against Apple Corporation for infringing four VirnetX patents, marking the fourth time a federal jury has found that Apple has infringed VirnetX’s patented technology. The jury also found that Apple willfully infringed VirnetX’s patents.
The verdict covers issues of infringement by Apple’s redesigned VOD (VPN on Demand) in iOS 7 to iOS 11, the redesigned FaceTime in iOS 7 to iOS 11 and OS X 10.9 and later.
“We are extremely pleased with the jury’s verdict. We believe that by standing on truth and integrity the verdict is fair and appropriate,” said Kendall Larsen, VirnetX CEO and President. “This is the fourth time a jury has confirmed that Apple has been using the technology developed by our inventors.”
Might just be simply ATM selling so VHC can stay afloat till Apple FINALLY pays up. Just a matter of time until AAPL runs out of time delaying and gets slapped with further punitive damages, or an injunction. I know they can afford it, but the longer they delay, the more it's gonna cost AAPL
Kinda too late for a license deal?
Maybe they are all just sitting back and watching. things. like. this. happen a LOT:
Caldwell Cassady & Curry Helps VirnetX VHC Win $502.6 Million Verdict Against Apple
BY PR Newswire
— 9:34 AM ET 04/11/2018
and...
Law Firm: Seven-Day Trial Focused on Four VirnetX Patents >VHC
DJ REALTIME NEWS – 9:39 AM ET 04/11/2018
Deals take tiiiime.
Any chance of an upcoming effort to kick this back up over a dollar so as not to run afoul of NASDAQ listing requirements?
Vuzix Files Defamation Suit vs Short Seller, Seeks $80 Mln Damages
BY MT Newswires
— 4:21 PM ET 04/06/2018
I just recieved a push notification on my iPhone settings for Two Factor Authentication. Looks like Apple will be paying Strikeforce for billions of copies.
When /if they announce gas stations in China accepting Cryptocurrency for fuel, this goes nuts again don't you think?
Seems like the chart was right. Good run up to 1.50s. Looks like time to do it again? Or wait for another golden cross?